Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain Fvs

International Journal of Cancer

Volumn 94, Issue 5, 2001, Pages 717-726

  Pavlinkova, Gabriela ^a   Colcher, David ^b   Booth, Barbara J M ^a   Goel, Apollina ^a   Wittel, Uwe A ^a   Batra, Surinder K ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

^b Coulter Pharmaceutical Inc ^*  (United States)

Author keywords

Antibody engineering; Antigen binding; Antiidiotypic antibodies; Monoclonal antibodies; Single chain antibodies

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CC49;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BINDING SITE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOGENICITY; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; SURFACE PLASMON RESONANCE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS;

EID: 0035545989     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1523     Document Type: Article

References (58)

1. Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma
2. A phase II trial of murine monoclonal antibody 17-1A and interferon-gamma: Clinical and immunological data
3. Development of human anti-murine antibody (HAMA) response in patients
4. Recombinant chimeric monoclonal antibodies
5. Humanized antibodies
6. Structural correlates of an anticarcinoma antibody: Identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only
7. The anti-idiotypic response by cynomolgus monkeys to humanized anti-Tac is primarily directed to complementarity-determining regions H1, H2, and L3
8. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual antiidiotypic responses
9. CDR substitutions of a humanized monoclonal antibody (CC49): Contributions of individual CDRs to antigen binding and immunogenicity
10. A tumor-associated antigen in carcinoma of the pancreas defined by monoclonal antibody B72.3
11. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3
12. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49
13. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: A phase I trial
14. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: A phase I trial
15. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer
16. Low-dose monoclonal antibody CC49 administered sequentially with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal cancer
17. Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72
18. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma
19. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO 17-1A
20. Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody
21. Charge-modified single chain antibody constructs of monoclonal antibody CC49: Generation, characterization, pharmacokinetics, and biodistribution analysis
22. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts
23. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct
24. Pharmacokinetics and biodistribution of a light-chain-shuffled CC49 single-chain Fv antibody construct
25. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49
26. Effects of genetic engineering on the pharmacokinetics of antibodies
27. Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: Expression, purification, and characterization
28. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
29. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms
30. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability
31. Multivalent Fvs: Characterization of single-chain Fv oligomers and preparation of a bispecific Fv
32. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49
33. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen
34. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies
35. A spectrum of monoclonal antibodies reactive with human mammary tumor cells
36. Protein measurement with Folin phenol.
37. Preferential use of a H chain V region in antitumor-associated glycoprotein-72 monoclonal antibodies
38. Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli
39. Construction of penP delta 1, Bacillus licheniformis 749/C beta-lactamase lacking site for lipoprotein modification. Expression in Escherichia coli and Bacillus subtilis
40. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
41. Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody
42. Site-specific photobiotinylation of immunoglobulins, fragments and light chain dimers
43. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma
44. Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody
45. Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: A phase I study
46. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients
47. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250
48. Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer
49. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma
50. Rhenium-186-labeled chimeric antibody NR-LU-13: Pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10
51. Reshaping human antibodies: Grafting an antilysozyme activity
52. Humanized antibodies for therapy
53. Dissection of the combining site in a humanized anti-Tac antibody
54. Anatomy of the antibody molecule
55. Single-chain antigen-binding proteins
56. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv
57. Tumor localization of anti-CEA single-chain Fvs: Improved targeting by non-covalent dimers
58. Biodistribution of 18F- and 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts